Abstract
Heart failure is a common disease with high levels of morbidity and mortality. Current treatment comprises β-blockers, ACE inhibitors, aldosterone antagonists and diuretics. Variation in clinical response seen in patients begs the question of whether there is a pharmacogenetic component yet to be identified. To date, the genes most studied involve the β-1, β-2, α-2 adrenergic receptors and the renin-angiotensin-aldosterone pathway, mainly focusing on SNPs. However results have been inconsistent. Genome-wide association studies and next-generation sequencing are seen as alternative approaches to discovering genetic variations influencing drug response. Hopefully future research will lay the foundations for genotype-led drug management in these patients with the ultimate aim of improving their clinical outcome.
Original language | English |
---|---|
Pages (from-to) | 1817-1827 |
Number of pages | 11 |
Journal | Pharmacogenomics |
Volume | 16 |
Issue number | 16 |
DOIs | |
Publication status | Published - Nov 2015 |
Keywords
- candidate genes
- genome-wide association study
- heart failure
- pharmacogenetics
- pharmacogenomics